Top ▲
Target not currently curated in GtoImmuPdb
Target id: 1984
Nomenclature: cyclin-dependent kinase like 3
Abbreviated Name: CdkL3
Gene and Protein Information | ||||||
Species | TM | AA | Chromosomal Location | Gene Symbol | Gene Name | Reference |
Human | - | 592 | 5q31.1 | CDKL3 | cyclin dependent kinase like 3 | |
Mouse | - | 595 | 11 B1.3 | Cdkl3 | cyclin dependent kinase like 3 | |
Rat | - | 593 | 10q22 | Cdkl3 | cyclin-dependent kinase-like 3 |
Previous and Unofficial Names |
NKIAMRE | serine/threonine kinase NKIATRE | serine/threonine kinase NKIATRE beta |
Database Links | |
Alphafold | Q8IVW4 (Hs), Q8BLF2 (Mm), Q9JM01 (Rn) |
BRENDA | 2.7.11.22 |
ChEMBL Target | CHEMBL1163117 (Hs) |
Ensembl Gene | ENSG00000006837 (Hs), ENSMUSG00000020389 (Mm), ENSRNOG00000059485 (Rn) |
Entrez Gene | 51265 (Hs), 213084 (Mm), 60396 (Rn) |
Human Protein Atlas | ENSG00000006837 (Hs) |
KEGG Enzyme | 2.7.11.22 |
KEGG Gene | hsa:51265 (Hs), mmu:213084 (Mm), rno:60396 (Rn) |
OMIM | 608459 (Hs) |
Pharos | Q8IVW4 (Hs) |
RefSeq Nucleotide | NM_001113575 (Hs), NM_001166653 (Mm), NM_021772 (Rn) |
RefSeq Protein | NP_001107047 (Hs), NP_001160125 (Mm), NP_068540 (Rn) |
UniProtKB | Q8IVW4 (Hs), Q8BLF2 (Mm), Q9JM01 (Rn) |
Wikipedia | CDKL3 (Hs) |
Enzyme Reaction | ||||
|
DiscoveRx KINOMEscan® screen | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
A screen of 72 inhibitors against 456 human kinases. Quantitative data were derived using DiscoveRx KINOMEscan® platform. http://www.discoverx.com/services/drug-discovery-development-services/kinase-profiling/kinomescan Reference: 1-2 |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Key to terms and symbols | Click column headers to sort | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Target used in screen: CDKL3 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Displaying the top 10 most potent ligands View all ligands in screen » |
1. Davis MI, Hunt JP, Herrgard S, Ciceri P, Wodicka LM, Pallares G, Hocker M, Treiber DK, Zarrinkar PP. (2011) Comprehensive analysis of kinase inhibitor selectivity. Nat Biotechnol, 29 (11): 1046-51. [PMID:22037378]
2. Wodicka LM, Ciceri P, Davis MI, Hunt JP, Floyd M, Salerno S, Hua XH, Ford JM, Armstrong RC, Zarrinkar PP et al.. (2010) Activation state-dependent binding of small molecule kinase inhibitors: structural insights from biochemistry. Chem Biol, 17 (11): 1241-9. [PMID:21095574]
Cyclin-dependent kinase-like (CDKL) family: cyclin-dependent kinase like 3. Last modified on 29/01/2016. Accessed on 18/01/2025. IUPHAR/BPS Guide to PHARMACOLOGY, https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1984.